https://www.selleckchem.com/pr....oducts/wortmannin.ht
Facial angiofibromas may be present since early childhood in individuals with tuberous sclerosis complex (TSC), causing substantial cosmetic disfigurement. Current therapies are partially effective, but they are uncomfortable, produce scarring, and are especially expensive. The aim of the present study was to evaluate the efficacy of oral everolimus for TSC-associated angiofibromas. This retrospective study included TSC patients being treated with oral everolimus for subependymal giant cell astrocytomas (SEGAs) and angiomyolipomas (A